

Sminu Bose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3789961/publications.pdf>

Version: 2024-02-01

9
papers

237
citations

1937685

4
h-index

1872680

6
g-index

9
all docs

9
docs citations

9
times ranked

244
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucose Metabolism in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1063, 3-12.	1.6	139
2	Glucose Metabolism in Cancer: The Warburg Effect and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1311, 3-15.	1.6	76
3	Novel Therapeutics in the Treatment of Uterine Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 900-909.	3.8	9
4	Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e150-e153.	2.4	7
5	A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11587-TPS11587.	1.6	3
6	Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11509-11509.	1.6	3
7	Abstract 784A: Profiling pancreatic cancer metabolism and tumor microenvironment for therapy. , 2012, , .		0
8	Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e23518-e23518.	1.6	0
9	CDK4/6 Inhibition With Anti-“PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD-“1 Alone. <i>JCO Precision Oncology</i> , 2022, , .	3.0	0